TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11180040

Group type: EXPERIMENTAL
Intervention: ADL 8-2698 (4 mg) with intravenous morphine (0.05 mg x kg(‐1))
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intravenous morphine (0.05 mg x kg(‐1))
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ADL 8-2698 (4 mg) with intravenous morphine (0.15 mg/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo with intravenous morphine (0.15 mg/kg)
Number of subjects: 59
Study: 9895052

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Mechanical lithotripsy (ML)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Overall (both groups)
Number of subjects: 92
Study: 8043892

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion for improvement of glycaemic control
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Reduced insulin dose
Number of subjects: 21

Group type: COMPARATOR
Intervention: Increased insulin dose
Number of subjects: 21
Study: 3054433

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (500 kcal/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 15
Study: 4951237

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 48
Study: 31178499

Group type: EXPERIMENTAL
Intervention: Medication adherence for phosphate binders
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Medication adherence for antidiabetic medications
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Reason for missed dose
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Patient preference for oral medication (mental burden present)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Patient preference for oral medication (no mental burden)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Patient preference for oral medication (neither)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Reduction of mental burden by eliminating 1 medication
Number of subjects: 524
Study: 28613121

Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC) system using mobile phones for data collection
Number of subjects: 25089

Group type: EXPERIMENTAL
Intervention: Women's groups intervention
Number of subjects: 25089

Group type: EXPERIMENTAL
Intervention: Food transfers intervention
Number of subjects: 25089

Group type: EXPERIMENTAL
Intervention: Cash transfers intervention
Number of subjects: 25089
Study: 26433819

Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice-daily) and Trametinib (2 mg once-daily)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Vemurafenib (960 mg twice-daily)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib
Number of subjects: 704
Study: 23611915

Group type: EXPERIMENTAL
Intervention: Neuraxial block
Number of subjects: 8351

Group type: EXPERIMENTAL
Intervention: Thoracic epidural with general anaesthesia
Number of subjects: 8351
Study: 21863678

Group type: EXPERIMENTAL
Intervention: Mometasone spray
Number of subjects: 42

Group type: COMPARATOR
Intervention: NSS (Normal Saline Solution)
Number of subjects: 42
Study: 19856872

Group type: EXPERIMENTAL
Intervention: Complex compound of Cu(II) (dinitrate (V) di (3,4,5‐trimethyl‐N1‐pyrazol‐kappaN2) copper (II))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no Cu(II) compound)
Number of subjects: 0
Study: 16960473

Group type: EXPERIMENTAL
Intervention: Citalopram (a selective serotonin reuptake inhibitor)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Buspirone (5-HT1a receptor-specific challenge)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Citalopram and Buspirone
Number of subjects: 21
Study: 15064089

Group type: EXPERIMENTAL
Intervention: Androgen replacement therapy
Number of subjects: 0
Study: 10227067

Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 10
Study: 8818855

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg once daily for 3 days)
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Comparator agents (amoxycillin, co-amoxiclav, cefixime, cefaclor, clarithromycin, erythromycin, penicillin V, cloxacillin, or roxithromycin)
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Comparator agents
Number of subjects: 4500
Study: 2004477

Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms i.v. in bolus) plus rhEPO (40 U/kg in constant infusion for 30 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: GHRH (100 micrograms i.v. in bolus)
Number of subjects: 14
Study: 6338155

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 1086
Study: 29442476

Group type: EXPERIMENTAL
Intervention: Serum ferritin and iron levels at 12 gestational weeks in GDM group
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Cut-off values of serum ferritin and iron at 12 gestational weeks
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Early detection of serum iron and ferritin levels
Number of subjects: 362
Study: 28866468

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (blue-tinted water)
Number of subjects: 66
Study: 27658925

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (30 min of moderate intensity walking and stretching exercises for 16 months)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 29
Study: 24717427

Group type: EXPERIMENTAL
Intervention: ART-naive children
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: ART-experienced children
Number of subjects: 496

Group type: COMPARATOR
Intervention: HIV-uninfected controls
Number of subjects: 496
Study: 22076595

Group type: EXPERIMENTAL
Intervention: Chewing gum for a minimum of 90 min/day (n = 102)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Printed nutrition information only (n = 99)
Number of subjects: 201
Study: 21209993

Group type: EXPERIMENTAL
Intervention: Denzir (DZ) system restorations
Number of subjects: 18

Group type: COMPARATOR
Intervention: In‐Ceram Zirconia (InZ) system restorations
Number of subjects: 18
Study: 18495964

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (100 mg of elemental iron)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (various doses ranging from 20 to 500 mg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 110
Study: 15845681

Group type: EXPERIMENTAL
Intervention: N(2)O anesthesia
Number of subjects: 35

Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 35
Study: 13680198

Group type: EXPERIMENTAL
Intervention: Oropharyngo‐oesophageal scintigraphy (OPES)
Number of subjects: 16
Study: 14590217

Group type: EXPERIMENTAL
Intervention: Simulating head injury with warning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulating head injury without warning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naïve malingerers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warned malingerers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forced-choice measure
Number of subjects: 0
Study: 8555470

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (45 mg/kg/d for 4 consecutive days)
Number of subjects: 10
Study: 1829969

Group type: EXPERIMENTAL
Intervention: Clinical examination, chest radiography, and electrocardiography
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined clinical examination, radiography, and electrocardiography
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 81
Study: 6823889

Group type: EXPERIMENTAL
Intervention: Asian meals containing contamination iron
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: In vitro method for measuring isotopic exchange
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Consideration of contamination iron in iron absorption measurements
Number of subjects: 12
Study: 31956250

Group type: EXPERIMENTAL
Intervention: Thoracoscopic esophagectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study: 30254212

Group type: EXPERIMENTAL
Intervention: BRAF fusions identified in the study
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exogenously expressed BRAF fusions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BRAF fusions (including SEPT3‐BRAF)
Number of subjects: 60
Study: 29118383

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (1 × 108 colony forming units)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri density
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: E. coli density
Number of subjects: 65
Study: 26409670

Group type: EXPERIMENTAL
Intervention: Sublingual captopril
Number of subjects: 212

Group type: COMPARATOR
Intervention: Oral captopril
Number of subjects: 212
Study: 25365798

Group type: COMPARATOR
Intervention: Intracranial area (ICA) measurement
Number of subjects: 42
Study: 23144438

Group type: EXPERIMENTAL
Intervention: Preperitoneal continuous wound infusion (CWI) with ropivacaine 0.2% at 10 mL/h for 48 hours
Number of subjects: 106

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) with ropivacaine 0.2% at 10 mL/h for 48 hours
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Preperitoneal continuous wound infusion (CWI)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 106
Study: 20102913

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 900
Study: 18928218

Group type: EXPERIMENTAL
Intervention: Mitomycin C (1 mg/ml applied at the site of discectomy for 5 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (lumbar microdiscectomy without mitomycin C application)
Number of subjects: 60
Study: 16086983

Group type: EXPERIMENTAL
Intervention: Internet-administered self-help plus minimal therapist contact via e-mail
Number of subjects: 49

Group type: COMPARATOR
Intervention: Traditional individual cognitive behaviour therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Comparison between Internet group and live group
Number of subjects: 49
Study: 12204013

Group type: EXPERIMENTAL
Intervention: Annual mammography, breast physical examination, and instruction on breast self-examination (mammography group)
Number of subjects: 50430

Group type: COMPARATOR
Intervention: Usual community care after a single breast physical examination and instruction on breast self-examination (usual care group)
Number of subjects: 50430
Study: 10614260

Group type: EXPERIMENTAL
Intervention: Intensive diabetes foot education program (2 sessions conducted by a nurse diabetes educator 3 months apart)
Number of subjects: 100
Study: 8349938

Group type: EXPERIMENTAL
Intervention: Methacholine nasal challenge (1 to 25 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (nonatopic subjects)
Number of subjects: 58
Study: 3770869

Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation (1 g/day)
Number of subjects: 18
Study: 29904005

Group type: EXPERIMENTAL
Intervention: Randomized Intensity Difference (RID) operator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RandomFerns and RandomForests classifiers with RID operators
Number of subjects: 0
Study: 26751259

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 62
Study: 26529960

Group type: EXPERIMENTAL
Intervention: Anaesthesia complications during caesarean delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variations in skill/training and equipment utilization
Number of subjects: 0
Study: 22767199

Group type: EXPERIMENTAL
Intervention: Intratympanic steroids (4 injections of 0.3 ml dexamethasone at 8 mg/ml and 0.2 ml hyaluronic acid 0.2%)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard therapy (prednisolone, hydroxyethyl starch, pentoxyfylline)
Number of subjects: 48
Study: 21607581

Group type: COMPARATOR
Intervention: Water swallow test (WST)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bolus swallow test + Saliva swallow test (BST + SST)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fiberoptic endoscopic evaluation of swallowing (FEES)
Number of subjects: 62
Study: 17963825

Group type: EXPERIMENTAL
Intervention: Monthly fluorouracil (1000 mg/m2/day i.v. for 5 days) plus cisplatin (20 mg/m2/day i.v.)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Weekly cisplatin (30 mg/m2 i.v.)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Monthly fluorouracil plus cisplatin
Number of subjects: 158

Group type: COMPARATOR
Intervention: Weekly cisplatin
Number of subjects: 158
Study: 16570892

Group type: EXPERIMENTAL
Intervention: Immediate release of drain following release of tourniquet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed release of the drain clamp by one hour
Number of subjects: 100
Study: 12935406

Group type: EXPERIMENTAL
Intervention: Nonwashed shed mediastinal blood (Group 1, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Banked blood (Group 2, n = 30)
Number of subjects: 60
Study: 11074080

Group type: EXPERIMENTAL
Intervention: Emotional stimuli (pleasant or unpleasant) presented in the same or opposite spatial location to the target
Number of subjects: 18

Group type: COMPARATOR
Intervention: Neutral picture
Number of subjects: 18
Study: 9760148

Group type: EXPERIMENTAL
Intervention: mini‐ICE/ICE chemotherapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: 5 + 2/7 + 3 chemotherapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PBSC transplantation
Number of subjects: 43
Study: 8090095

Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 89
Study: 3290430

Group type: EXPERIMENTAL
Intervention: Tetracycline irrigation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SC/RP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 7

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 7
Study: 30756274

Group type: EXPERIMENTAL
Intervention: Pivotal Response Intervention for Social Motivation (PRISM)
Number of subjects: 0
Study: 28763279

Group type: EXPERIMENTAL
Intervention: synthetic feline facial pheromone
Number of subjects: 336

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 336
Study: 25832443

Group type: EXPERIMENTAL
Intervention: 400 mg/day of DHA supplementation for two weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study: 24064942

Group type: EXPERIMENTAL
Intervention: MICS IOL (Acri.Smart 46S=CT SHERIS 209M)
Number of subjects: 25

Group type: COMPARATOR
Intervention: SICS IOL (AcriLyc 53N = CT 53N)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MICS IOL
Number of subjects: 25

Group type: COMPARATOR
Intervention: SICS IOL
Number of subjects: 25
Study: 21421092

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5mg
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1434
Study: 18946573

Group type: EXPERIMENTAL
Intervention: Unreamed interlocking nails
Number of subjects: 131

Group type: COMPARATOR
Intervention: Ender nails
Number of subjects: 131
Study: 16597214

Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 48
Study: 12743539

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus 5‐methoxytryptamine (5‐MTT) 1 mg/day orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin plus etoposide)
Number of subjects: 20
Study: 10983211

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study: 8818067

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 4019

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4019
Study: 1543187

Group type: EXPERIMENTAL
Intervention: Intervention group (52 pairs)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (51 pairs)
Number of subjects: 103
Study: 3978014

Group type: EXPERIMENTAL
Intervention: EMLA 5% cream (Eutectic Mixture of Local Anaesthetics)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30880074

Group type: EXPERIMENTAL
Intervention: Serenoa repens extract (320 mg)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 30281182

Group type: EXPERIMENTAL
Intervention: 100% oxygen (group O2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 50% oxygen and 50% nitrous oxide (group N2O)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 100% oxygen with a bolus of 3 μg/kg fentanyl (group FENTANYL)
Number of subjects: 72
Study: 27518208

Group type: EXPERIMENTAL
Intervention: Cone Beam CT (CBCT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Multislice CT (MSCT)
Number of subjects: 9
Study: 25250780

Group type: EXPERIMENTAL
Intervention: Testoviron depot (i.m.: 100 mg/10 days)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Testosterone gel (50 mg/die)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (i.m.: 1,000 mg every 6 weeks for the first 6 weeks and then every 12 weeks)
Number of subjects: 45
Study: 22765768

Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ivabradine 10 mg after pre-treatment with phenytoin 150 mg
Number of subjects: 18
Study: 21333193

Group type: EXPERIMENTAL
Intervention: Laparoscopic occlusion
Number of subjects: 96

Group type: COMPARATOR
Intervention: Embolization
Number of subjects: 96
Study: 17667033

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 16220082

Group type: EXPERIMENTAL
Intervention: INH-A21 750 mg/kg
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study: 12145376

Group type: EXPERIMENTAL
Intervention: Formal staff management (FSM)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional staff management (CSM)
Number of subjects: 106
Study: 10369059

Group type: EXPERIMENTAL
Intervention: Primed with African American stereotypes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Primed with neutral words
Number of subjects: 60
Study: 7589766

Group type: EXPERIMENTAL
Intervention: 5 mg sustained-release isradipine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 4 mg lacidipine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 2289389

Group type: EXPERIMENTAL
Intervention: Tetracycline (250 mg, five-day course every six hours)
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Ampicillin (250 mg, five-day course every six hours)
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1350
Study: 471860

Group type: EXPERIMENTAL
Intervention: Chapman‐Gray Index
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norris Index
Number of subjects: 0
Study: 31006930

Group type: COMPARATOR
Intervention: Routine Monitoring
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Contralateral Prophylactic Mastectomy (CPM)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Traders (willing to swap between options)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Less-intrusive monitoring methods
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Involvement in decision-making
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Cancer concern
Number of subjects: 464
Study: 27346393

Group type: EXPERIMENTAL
Intervention: Semi-occluded vocal tract exercise with a ventilation mask
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no ventilation mask)
Number of subjects: 30
Study: 25861836

Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: FOLFIRI-C (FOLFIRI plus cetuximab)
Number of subjects: 89

Group type: COMPARATOR
Intervention: FOLFIRI-C
Number of subjects: 89
Study: 23608668

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study: 21666156

Group type: EXPERIMENTAL
Intervention: One dose of Edmonston-Zagreb measles vaccine (MV) at 6 and 9 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Two doses of Edmonston-Zagreb measles vaccine (MV) at 6 and 9 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group: Measles vaccine at 9 months only (for HIV-uninfected children)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HIV-infected children receiving measles vaccine
Number of subjects: 22
Study: 19626051

Group type: EXPERIMENTAL
Intervention: Alemtuzumab monotherapy as first-line therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring CMV reactivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of alemtuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alemtuzumab combination therapy and consolidation therapy
Number of subjects: 0
Study: 16939937

Group type: EXPERIMENTAL
Intervention: Hair analysis using immunoassay techniques
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Self-reported frequency of heroin use
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Sectional hair analysis
Number of subjects: 382
Study: 14695461

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (n=89)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Normal saline (control group, n=91)
Number of subjects: 180